Refine by
Brain Cancer Suppliers & Manufacturers
31 companies found
based inBingham, MICHIGAN (USA)
In 2017, a group of internationally-recognized MRI industry professionals and entrepreneurs founded SpinTech, Inc. with the goal of transforming advanced MRI techniques, previously reserved only for the research realm, into practical applications to ...
based inAlmere, NETHERLANDS
We’re proud of what Medstone has achieved so far. We’ve built a platform for pharmacists, we offer artificial intelligence solutions for scientific analyses, and we have our own pharmaceutical wholesale. We do all these things because we have one ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
Our lead product candidate, Trans sodium crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and ...
based inAarhus C, DENMARK
Cercare Medical is based on +25 years of research in perfusion imaging and artificial intelligence. Our novel biomarkers provide unparalleled patient insights. We are bridging the gap between science and clinical practice. With our amazing ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
based inBuford, GEORGIA (US) (USA)
Continuing To Do More To Save More Lives. Theragenics was founded in 1981 and quickly became a global leader in the manufacture of radioactive brachytherapy seeds for the treatment of localized prostate cancer. We began diversifying operations in ...
based inFoothill Ranch, CALIFORNIA (USA)
TAE Life Sciences (TLS) is a biologically-targeted radiation therapy company focused on developing novel treatments to improve the lives of patients with invasive, recurrent and difficult to treat cancers. Founded in 2017, TLS is the only company ...
TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), a ...
based in, CHINA
Mol Scientific provides customized peptide synthesis services including linear peptides, modified peptides, protein cross-linked peptides and more. Mol Scientific is a national high-tech enterprise, committed to providing high quality products and ...
![Mol Scientific - Model MPE0009823 - Deleted in malignant brain tumors 1 protein [2385-2413] peptide](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyNzQ2MS9pbWFnZXMvMTI3NDYxXzBfMjAyMjA4MTYwNzQ1MDkxNjk5ODQ1XzQwMC5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MTQzLCJoZWlnaHQiOjEwMn19fQ== "Mol Scientific - Model MPE0009823 - Deleted in malignant brain tumors 1 protein [2385-2413] peptide")
Mol Scientific offer high-quality Deleted in malignant brain tumors 1 protein [2385-2413] peptide product(MPE0009823). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
based inNew York City, NEW YORK (USA)
Lauren Sciences is a privately-held New York biotechnology company focused on developing its V-Smart platform to create a robust pipeline of V-Smart therapeutics consisting of central nervous system (CNS)-active drugs that normally do not cross the ...
based inRockville, MARYLAND (USA)
Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. ...
Building on the clinical advancement of VCN-01, Theriva developed the Albumin Shield™ technology to protect oncolytic viruses from circulating anti-oncolytic virus antibodies after systemic administration. We anticipate that this technology ...
based inMinnetonka, MINNESOTA (USA)
Monteris Medical was founded in 1999 with the sole focus to help patients suffering from neurological diseases. The company’s goal remains: to create a minimally invasive surgical option for use in the brain. Monteris is a private equity backed ...
Dependable skull fixation for neurosurgical devices. The only cranial fixation bolt with a robotic interface to enable precise laser delivery. ...
based inTampa, FLORIDA (USA)
infuseon therapeutics, inc. was founded in 2012 by Cleveland Clinic for the purpose of developing its patented unique therapeutic delivery device, the Cleveland Multiport Catheter™. This multiport convection-enhanced delivery catheter was designed ...
based inTempe, ARIZONA (USA)
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
To accelerate the development of cancer immunotherapy, it is essential to systematically identify tumor antigens that are truly tumor-specific, patient-shared, stably expressed (i. e., cloned) and immunogenic in all malignant cells. ...
based inMARSEILLE, FRANCE
Founded in 2005, by Alexandre TOKAY, CEO, and Dr. Michel KHRESTCHATISKY, Scientific Advisor, VECT-HORUS is a spin-off of the NICN UMR7259 (CNRS and Aix-Marseille University) now Institute for NeuroPhysiopathology (INP) directed by Dr. Michel ...
based inBerlin, GERMANY
ALBEGA Medical is a newly established pharmaceutical company developing novel radiopharmaceuticals in oncology. Our lead compound is Tetrofosmin (TTF) that we are developing in 3 indications: GLIOTECT - a novel diagnostic for brain tumors, GLIOTHER ...
based inBurton upon Trent, UNITED KINGDOM
The Asbestos Testing and Consultancy Association (ATaC) is the leading trade association in the UK for the asbestos testing and consulting services sector. ATaC has represented the interests of asbestos testing and consultancy specialists for over ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
based inTucson, ARIZONA (USA)
Novel therapeutics are lacking for Brain Cancer. Only four of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009 and did not extend life expectancy. Patients deserve better ...
Only 4 of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009, but this medicine did not extend life expectancy. Patients deserve better ...